Video

Results of the VISION Trial and Real-World Use of 177Lu-PSMA-617 in mCRPC

Reflections on results of the VISION trial, which utilized 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected